CASP4 and central nervous system cancer: Similarly, a subgroup analysis in TCGA to analyze the prognostic impact of CASP4 in different glioma grades also showed that high CASP4 expression was associated with poorer OS in WHO G3 (HR = 1.97, 95% CI = 0.93–4.07, Cox P = 0.004, Figure 3D) and WHO G4 (HR = 1.42, 95% CI = 1.01–2.00, Cox P = 0.044, Figure 3E).